Breast Unit, First Department of Propaedeutic Surgery, Hippokratio Hospital, School of Medicine, University of Athens, Greece.
In Vivo. 2011 Jul-Aug;25(4):669-72.
Heat-shock protein 90 (HSP90) is an abundant protein in mammalian cells. It interacts with a variety of proteins that play key roles in breast neoplasia. This is the first study to assess serum levels of HSP90 in atypical ductal hyperplasia (ADH), lobular neoplasia (LN), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and infiltrative lobular carcinoma (ILC).
Serum concentrations of HSP90 in women with benign (n=34), ADH (n=26), DCIS (n=30), IDC (n=29), LN (n=20) and ILC (n=9) lesions were determined with immunoenzymatic assays. For the evaluation of serum concentrations along the transition from benign through precursor and preinvasive to invasive lesion, the severity of diagnosis was treated as an ordinal variable.
No significant association was demonstrated between serum HSP90 levels and the severity of the lesion in ductal and lobular series. The post hoc comparison between the lobular and ductal precursor lesions (i.e. ADH vs. LN) did not yield a statistically significant difference. Similarly, the post hoc comparison between the lobular and ductal invasive carcinomas (i.e. IDC vs. ILC) did not point to a statistically significant difference.
This is the first study evaluating HSP90 serum levels in both lobular and ductal lesions of the breast. Contrary to published pathological findings according to which HSP90 exhibits significant variability along both series, such a finding was not replicated for the level of serum HSP90 concentrations.
热休克蛋白 90(HSP90)是哺乳动物细胞中丰富的蛋白质。它与在乳腺癌发生中起关键作用的多种蛋白质相互作用。这是第一项评估非典型导管增生(ADH)、小叶肿瘤(LN)、导管原位癌(DCIS)、浸润性导管癌(IDC)和浸润性小叶癌(ILC)中血清 HSP90 水平的研究。
采用免疫酶分析法测定 34 例良性病变(n=34)、ADH(n=26)、DCIS(n=30)、IDC(n=29)、LN(n=20)和 ILC(n=9)患者血清 HSP90 浓度。为了评估从良性病变到前驱病变和癌前病变再到浸润性病变的血清浓度变化,将诊断严重程度视为有序变量。
在导管和小叶系列中,血清 HSP90 水平与病变严重程度之间没有显著相关性。在小叶和导管前驱病变(即 ADH 与 LN)之间的事后比较没有产生统计学上的显著差异。同样,在小叶和导管浸润性癌(即 IDC 与 ILC)之间的事后比较也没有指向统计学上的显著差异。
这是第一项评估乳腺小叶和导管病变中 HSP90 血清水平的研究。与发表的病理发现相反,根据该发现,HSP90 在两个系列中均表现出显著的变异性,但这种发现并未在血清 HSP90 浓度水平上得到复制。